The founders of Crinetics Pharmaceuticals Inc. aim to treat endocrine-related diseases and cancers with novel molecules that target peptide hormone receptors. It has been working intensively to apply the concept of biased agonism to the large and popular class of drug targets known as G-protein coupled receptors; it will initially seek to develop a treatment for acromegaly.
Crinetics Pharmaceuticals Inc.
6181 Cornerstone Court
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.
Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.
Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.
